159 related articles for article (PubMed ID: 26131374)
41. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA.
Morrato EH; Ling SB
Med Care; 2012 Nov; 50(11):970-86. PubMed ID: 23047787
[TBL] [Abstract][Full Text] [Related]
42. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.
Ross JS; Mulvey GK; Hines EM; Nissen SE; Krumholz HM
PLoS Med; 2009 Sep; 6(9):e1000144. PubMed ID: 19901971
[TBL] [Abstract][Full Text] [Related]
43. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
44. An Assessment of Publication Status of Pediatric Liver Transplantation Studies.
Breil T; Wenning D; Teufel U; Hoffmann GF; Ries M
PLoS One; 2016; 11(12):e0168251. PubMed ID: 27992485
[TBL] [Abstract][Full Text] [Related]
45. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
46. [Regulations concerning data transparency- a comparison between the USA and Europe].
Quack C
Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):183-8. PubMed ID: 21530907
[TBL] [Abstract][Full Text] [Related]
47. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
48. Reporting of results of interventional studies by the information service of the National Institutes of Health.
Shamliyan T
Clin Pharmacol; 2010; 2():169-76. PubMed ID: 22291502
[TBL] [Abstract][Full Text] [Related]
49. Study design, result posting, and publication of late-stage cardiovascular trials.
Kapelios CJ; Naci H; Vardas PE; Mossialos E
Eur Heart J Qual Care Clin Outcomes; 2022 May; 8(3):277-288. PubMed ID: 33098422
[TBL] [Abstract][Full Text] [Related]
50. Discontinuation and non-publication of surgical randomised controlled trials: observational study.
Chapman SJ; Shelton B; Mahmood H; Fitzgerald JE; Harrison EM; Bhangu A
BMJ; 2014 Dec; 349():g6870. PubMed ID: 25491195
[TBL] [Abstract][Full Text] [Related]
51. Public welfare agenda or corporate research agenda?
Singh A; Singh S
Mens Sana Monogr; 2005 Mar; 3(1):41-80. PubMed ID: 22679348
[TBL] [Abstract][Full Text] [Related]
52. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.
Zwierzyna M; Davies M; Hingorani AD; Hunter J
BMJ; 2018 Jun; 361():k2130. PubMed ID: 29875212
[TBL] [Abstract][Full Text] [Related]
53. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
54. Unpublished completed obstetric randomized clinical trials registered at ClinicalTrials.gov: how big is this issue?
Gupta M; Oliver EA; Chauhan SP; Wagner SM; Mol B; Berghella V
Am J Obstet Gynecol MFM; 2023 Sep; 5(9):101066. PubMed ID: 37419451
[TBL] [Abstract][Full Text] [Related]
55. Trial registration, publication rate and characteristics in the research field of otology: A cross-sectional study.
van Heteren JAA; van Beurden I; Peters JPM; Smit AL; Stegeman I
PLoS One; 2019; 14(7):e0219458. PubMed ID: 31291350
[TBL] [Abstract][Full Text] [Related]
56. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
[TBL] [Abstract][Full Text] [Related]
57. Publication proportions for registered breast cancer trials: before and following the introduction of the ClinicalTrials.gov results database.
Asiimwe IG; Rumona D
Res Integr Peer Rev; 2016; 1():10. PubMed ID: 29451530
[TBL] [Abstract][Full Text] [Related]
58. Meta-analysis: Problems with Russian Publications.
Verbitskaya EV
Int J Risk Saf Med; 2015; 27 Suppl 1():S89-90. PubMed ID: 26639728
[TBL] [Abstract][Full Text] [Related]
59. Has the FDA Amendments Act of 2007 impaired drug development?
Franson TR
Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
